27 September 2018 - NICE has published draft guidelines rejecting NHS use of CSL Behring’s Respreeza for treating emphysema in ...
26 September 2018 - Enzyme that selectively targets blood clots has received FDA fast track designation, allowing for expedited clinical development. ...
21 September 2018 - The safety and efficacy profile of BAY94-9027 has been demonstrated in more than five years of clinical ...
21 September 2018 - CHMP elects new chair and recommends thirteen medicines for approval. ...
12 September 2018 - Marketing authorisation will enable patient access to Veyvondi throughout Europe. ...
4 September 2018 - New formulation is manufactured using Grifols' sophisticated caprylate chromatography process according to the highest quality and safety ...
30 August 2018 - Jivi’s extended half-life allows for twice-weekly initial dosing / May be adjusted to every five days and ...
23 August 2018 - Public comment period now open until 20 September; requests to make oral comment during public meeting also ...
26 July 2018 - Prior approval supplement to amend the biologics license application for Bivigam is supported by data and documentation ...
23 July 2018 - PHARMAC invites proposals for the supply of Recombinant Factor VIII, Recombinant Factor IX and bypassing agents (Recombinant ...
2 July 2018 - Veyvondi is currently only approved in the US for adults with VWD. ...
21 June 2018 - Shire is the only drug developer to complete a paediatric study for the prophylactic treatment of hereditary ...
18 June 2018 - Octapharma announced today that the EMA has approved an extension of marketing authorisation for its human cell ...
31 May 2018 - New vial option delivers on CSL Behring’s promise to enhance current treatments and provide more alternatives to ...
23 May 2018 - FDA previously granted Coagadex orphan drug designation for the treatment of hereditary factor X deficiency. ...